We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATYR
376
aTyr Pharma
ATYR
$38.2M
| $22.9M | 0.05% |
14,666,600
+4,497,000
| +44% | +$7.82M |
|
377
Service Corp International
SCI
$11.1B
| $22.9M | 0.05% |
321,593
+19,436
| +6% | +$1.38M |
|
378
Lennox International
LII
$12.5B
| $22.8M | 0.05% |
42,672
+741
| +2% | +$365K |
|
379
Parker-Hannifin
PH
$117B
| $22.8M | 0.05% |
45,133
-13,517
| -23% | -$7.25M |
|
380
Azenta
AZTA
$1.45B
| $22.8M | 0.05% |
432,506
+25,586
| +6% | +$1.37M |
|
|
FISV
381
Fiserv Inc
FISV
$26.6B
| $22.6M | 0.05% |
151,647
+93,393
| +160% | +$14.1M |
|
382
Alnylam Pharmaceuticals
ALNY
$31.9B
| $22.5M | 0.05% |
92,608
-55,896
| -38% | -$8.82M |
|
383
NVR
NVR
$16.7B
| $22.2M | 0.05% |
2,926
+233
| +9% | +$1.78M |
|
384
Automatic Data Processing
ADP
$110B
| $22M | 0.05% |
92,324
+365
| +0.4% | +$89.6K |
|
385
ADMA Biologics
ADMA
$1.93B
| $22M | 0.05% |
1,969,811
+263,677
| +15% | +$2.21M |
|
386
PVH
PVH
$3.3B
| $21.9M | 0.05% |
207,205
-12,143
| -6% | -$1.37M |
|
387
FTI Consulting
FCN
$4.06B
| $21.8M | 0.05% |
101,287
+5,372
| +6% | +$1.15M |
|
388
Lantheus
LNTH
$6.58B
| $21.7M | 0.05% |
269,682
+24,326
| +10% | +$1.78M |
|
389
AstraZeneca
AZN
$251B
| $21.6M | 0.05% |
138,241
+3,284
| +2% | +$494K |
|
390
Invesco Senior Loan ETF
BKLN
$6.78B
| $21.1M | 0.05% |
1,004,245
| – | – |
|
391
Guidewire Software
GWRE
$12.4B
| $20.9M | 0.05% |
151,568
+8,558
| +6% | +$1.03M |
|
392
Nu Holdings
NU
$68.5B
| $20.7M | 0.05% |
1,608,917
-125,910
| -7% | -$1.47M |
|
393
Popular Inc
BPOP
$10.5B
| $20.6M | 0.05% |
233,353
+2,250
| +1% | +$196K |
|
394
InMode
INMD
$856M
| $20.5M | 0.05% |
1,125,017
+739,629
| +192% | +$13.6M |
|
395
RxSight
RXST
$234M
| $20.5M | 0.05% |
340,848
+43
| +0% | +$2.46K |
|
396
Cisco
CSCO
$434B
| $20.5M | 0.05% |
431,006
-303,704
| -41% | -$14.4M |
|
397
Live Nation Entertainment
LYV
$39.7B
| $20.4M | 0.05% |
218,082
+39,071
| +22% | +$3.69M |
|
398
Revvity
RVTY
$15.6B
| $19.9M | 0.05% |
190,030
+13,203
| +7% | +$1.4M |
|
|
TEM
399
Tempus AI
TEM
$12.5B
| $19.9M | 0.05% |
+568,173
| New | +$17.4M |
|
400
Allegro MicroSystems
ALGM
$6.2B
| $19.8M | 0.05% |
702,511
-307
| -0% | -$8.74K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.